Tradestie Institutional Equity Comparison Engine

COCP vs AIM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

COCP Overall Edge

COCP Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cocrystal Pharma, Inc. Common Stock (COCP) driven by superior Growth & Margin, Momentum & Technical while AIM counters with relative strength in Valuation. Fundamentally, COCP trades at N/M Forward P/E with -3063.6% operating margin (+26.9% YoY revenue) versus AIM at 2.0x Forward P/E and -11724.2% operating margin (+4.0% YoY). In options structure, COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AIM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner AIM
COCP N/M vs AIM 2.0x Fwd P/E
Growth & Margin Winner COCP
Op Margin -3063.6% vs -11724.2% ยท YoY +26.9% vs +4.0%
Momentum & Technical Winner COCP
1Y -3.0% vs -90.9% ยท 52W Pos 19% vs 1%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
1M Return -2.01%
1Y Return -2.96%
Forward P/E N/M
Unified AI Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0
AIM NYSE American
AIM ImmunoTech Inc.
Biological Products, (No Disgnostic Substances)
$0.13
-7.1% 1D
Market Cap $5.9M
1M Return -20.64%
1Y Return -90.89%
Forward P/E 2.0x
Unified AI Score
52.8 / 100 HOLD
Tech 54.0 Fund 57.0 Flow 50.0 Mom 68.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: COCP -2.96% AIM -90.89% Spread: +87.93 pp (COCP Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period COCP Revenue AIM Revenue COCP Op. Margin AIM Op. Margin Margin Edge
FY2018 N/A $0M N/A -3132.4% AIM
FY2019 $10M $0M -737.4% -8887.9% COCP
FY2020 $0M $0M -476.0% -9295.7% COCP
FY2021 N/A $0M N/A -13954.1% AIM
FY2022 N/A $0M N/A -14129.8% AIM
FY2023 N/A $0M N/A -15800.0% AIM
FY2024 N/A $0M N/A -11630.6% AIM
FY2025 N/A $0M N/A -13254.5% AIM

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: COCP (6) vs AIM (3)
Institutional Metric COCP AIM Criterion Row Winner
Market Capitalization Scale $19.6M $5.9M Larger Scale COCP
Trailing P/E Ratio Valuation N/M 2.0x Lower Multiple AIM
Forward P/E Ratio Valuation N/M 2.0x Lower Multiple AIM
Revenue Growth (YoY) Growth +26.9% +4.0% Higher Growth COCP
Operating Margin (TTM) Profitability -3063.6% -11724.2% Higher Margin COCP
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -311.7% -2382.3% Higher ROE COCP
52-Week Range Position Momentum 19% ($1โ€“$2) 1% ($0โ€“$2) Stronger Trend COCP
Beta / 30D Volatility Risk Regime 1.04ฮฒ ยท 54% Vol 0.32ฮฒ ยท 69% Vol Lower Realized Risk COCP
Unified Institutional Score Composite Signal 47.1 / 100 (HOLD) 52.8 / 100 (HOLD) Higher Composite AIM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full COCP vs AIM Buy Guide
COCP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live COCP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AIM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AIM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither COCP nor AIM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.